Bioventix plc
("Bioventix" or the "Company")
Director dealings
Bioventix plc (AIM: BVXP) was notified on 22 October 2014 that on the same day,
due to institutional investor demand, the following directors dealt in the
ordinary shares of 5 pence each ("Ordinary Shares") in the Company:
Name Position Type of Number Price Ordinary Percentage
transaction of per shares and of Ordinary
Ordinary Ordinary voting Shares and
Shares Share rights held voting
(pence) following rights held
the following
transaction the
transaction
Ian Non-Executive Disposal 8,000* 655.0 32,000 0.6
Nicholson Chairman
Peter Chief Executive Disposal 80,000** 655.0 761,176 15.1
Harrison
* 4,000 of which were held in the name of his wife
** 25,000 of which were held in the name of his wife
For further information please contact:
Bioventix plc Tel: 01252 728 001
Peter Harrison Chief Executive Officer
finnCap Ltd Tel: 020 7220 0500
Geoff Nash/Simon Hicks Corporate Finance
Steve Norcross Corporate Broking
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.